Clinical Trial Search

Primary: Pain Severity — 8.50; 8.31 score on a scale

Primary: Foot and Ankle Ability Measure (FAAM) — 66.2; 72.4; 69.9; 69.3 percentage of total score

Primary: Worst Pain — 5.96; 5.74; 3.91; 4.08 score — p=0.660

Primary: Patient Reported Pain Via the Universal Visual Analog Scale: Pass Criteria = at Least 25% Pain Reduction — 86 Percent of Patients meeting criteria

Primary: Foot and Ankle Ability Measure (FAAM) — 47.00; 45.28; 11.65; 11.72 Percentage of function

Primary: Visual Analog Scale Score - General Heel Tenderness — 46.7; 47.5 score on a scale

Primary: Ultrasonographic Evaluation of the Thickness of the Affected Plantar Fascia, in Longitudinal View. — 5.3; 4.7 millimeters

Primary: ML COP Velocity From Baseline to Post Intervention — 119.91; 118.91; 121.07; 116.99 % modulation — p=0.824

Primary: Plantar Flexor Muscle Strength — -8; 3; 6 Plantar Flexor Torque (Nm)

Primary: Number of Participants Who Attained a Change of -30% or Greater in the VAS Score — 23; 4 participants — p=<0.00005

Primary: Responders Rate at Week 6 (Pain While Moving) — 25.0; 5.0 Percentage of participants — p==0.182

Primary: Change From Baseline at Week 8 in the Visual Analog Scale (VAS) for Pain for the Foot — -41.6; -39.3 score on a scale

Primary: Change From Baseline at Week 8 in the Numeric Pain Rating Scale (NPRS) Score — -3.29; -3.25; -2.75 score on a scale

Primary: Average Percentage of Change as Reported Using Foot Function Index Pain Subscale — -54; -25 percentage of Change

Primary: Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT) — 16; 0; 2; 0 Participants